Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996910 | 0.84 | CYP3A4 (0.36) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL5236864 | 0.81 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL1996908 | 0.78 | CYP3A4 (0.47) | CYP3A4TRPA1 | |
| SCHEMBL1996913 | 0.76 | CYP3A4 (0.36) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL4774932 | 0.76 | CYP3A4 (0.45) | CYP3A4TRPA1 | |
| SCHEMBL4774942 | 0.76 | CYP3A4 (0.36) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL5788030 | 0.76 | CYP3A4 (0.36) | CYP3A4GABRA1GABRB2TRPA1 | |
| SCHEMBL964182 | 0.74 | CYP3A4 (0.37) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL27999562 | 0.73 | CYP3A4 (0.40) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL5788029 | 0.72 | CYP3A4 (0.45) | CYP3A4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | disclosed |
| EP-1368354-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Pfizer Products Inc. (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002070523-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-5766556-A | SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS, INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5714127-A | RESERVOIR RACKS WITH REACTION WELLS; GAS DISPERSION TUBES CONTAINING FILTERS; HOLDER BLOCK WITH APERTURES; MANIFOLD | WARNER-LAMBERT COMPANY (US) | 1998-02-03 | — | — | US | disclosed |
| US-5702672-A | REACTION TUBE COMPRISING GAS DISPERSION TUBE HAVING GROUNG GLASS JOINT SECTION | WARNER-LAMBERT COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| US-5612002-A | SYNTHESIS OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5593642-A | CONTAINMENT OF SOLID SUPPORT WITHIN A GAS DISPERSION TUBE | WARNER-LAMBERT COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5582801-A | HAVING PLURALITY OF REACTION TUBES WITH FILTERS ON LOWER ENDS, RESERVOIR WITH MEANS FOR RECEIVING FILTERS, HOLDER FOR SUPPORTING TUBES, MANIFOLD ENCLOSING UPPER ENDS, FASTENERS HOLDING TOGETHER HOLDER AND MANIFOLD, HOLDER AND RESERVOIR | WARNER-LAMBERT COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5567391-A | MULTICOMPARTMENT CHEMICAL REACTORS | WARNER-LAMBERT COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5565173-A | USED FOR SOLID-PHASE SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996030393-A1 | A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0663856-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5324483-A | Apparatus for multiple simultaneous synthesis | WARNER-LAMBERT COMPANY (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | PHKG1, PHKG2, MAP3K20 | CYP3A4 2186/4885GABRA1 3559/4885GABRB2 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.